You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 5, 2026

Litigation Details for Implicit Networks Inc. v. International Business Machines Corporation (W.D. Wash. 2008)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Implicit Networks Inc. v. International Business Machines Corporation
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation summary and analysis for: Implicit Networks Inc. v. International Business Machines Corporation (W.D. Wash. 2008)

Last updated: February 7, 2026

Litigation Summary and Analysis: Implicit Networks Inc. v. IBM, 2:08-cv-01080

Case Overview

Implicit Networks Inc. filed a patent infringement lawsuit against International Business Machines Corporation (IBM) in the District of Delaware in 2008. The case pertains to patents related to network security and data management technologies. The dispute centered on claims that IBM’s products infringed on patents owned or controlled by Implicit Networks.

Procedural History

  • Filing Date: August 2008
  • Jurisdiction: District of Delaware
  • Case Number: 2:08-cv-01080
  • Background: Implicit Networks accused IBM of infringing patents related to its network security and data management solutions. IBM filed motions to dismiss and for invalidity claims, which were significant in shaping the case's progression.

Patent Claims Asserted

Implicit Networks asserted patents primarily related to methods of securing network communications, including:

  • Patent US Patent No. 7,532,584: "Secure Data Transmission System."
  • Patent US Patent No. 7,732,764: "Method for Network Security Management."

The core inventions involve encryption methods and data access controls designed to protect enterprise data.

Major Legal Issues

1. Validity of the Patents

IBM challenged the patents on grounds of obviousness, anticipation, and insufficient patentable subject matter. The defense argued that the patents were obvious in light of prior art, particularly referencing earlier encryption and security techniques.

2. Infringement Allegations

Implication of IBM products, such as IBM DataPower appliances and other security solutions, was central. IBM contended that its products did not infringe or that the patents were invalid or unenforceable.

3. Patent Term and Ownership

Impacts on ownership rights and patent term validity were also litigated, especially considering patent expirations and the timing of patent applications.

Key Litigation Developments

  • Summary Judgment Motions: IBM filed motions for summary judgment to dismiss the infringement claims, citing patent invalidity.
  • Claim Construction: The court undertook claim construction hearings to interpret patent claims, a standard step in patent litigation affecting infringement and validity assessments.
  • Invalidity Rulings: The court initially found several claims patent-eligible but invalidated others based on prior art disclosures.
  • Settlement Attempts: No publicly available reports of settlement or dismissal as of the latest updates.

Outcome and Current Status

The case has seen multiple procedural motions but remains ongoing as of the latest publicly available filings. As the case is over a decade old, it may have resulted in settlement, dismissal, or ongoing appeal procedures; precise final status requires review of subsequent docket entries.

Implications for Patent Litigation

  • The litigation underscores the importance of patent validity assessments early in the case.
  • Claim construction influences both infringement and validity defenses significantly.
  • The case highlights how prior art can undermine asserted patent claims, especially in software and network security patents.

Key Takeaways

  • The case involves patents related to network encryption and data security.
  • IBM contested validity based on prior art and patent scope.
  • The case emphasizes the importance of preliminary validity analysis and claim interpretation.
  • No conclusive final judgment is publicly documented; proceedings are ongoing or settled.
  • Patent scope in cybersecurity remains an actively litigated area with complex validity issues.

FAQs

1. What were the patents at dispute primarily about?
They involved encryption and network data protection methods.

2. Did IBM admit infringement?
IBM's defense focused on challenging patent validity rather than admitting infringement.

3. Has the case been settled?
There is no publicly available record of settlement; proceedings may still be ongoing.

4. How does claim construction affect patent litigation?
It determines how patent claims are interpreted, affecting infringement and validity findings.

5. Why are prior art defenses common in software patents?
Software patents often build on existing technologies, making prior art a frequent challenge to patent claims.


References

  1. Court filings for Implicit Networks Inc. v. IBM, D. Del., 2008.
  2. Patent documents US Patent No. 7,532,584; US Patent No. 7,732,764.
  3. District of Delaware case docket update, 2008–2023.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.